Predictors of response to glimepiride in patients with type 2 diabetes mellitus - PubMed (original) (raw)
Clinical Trial
. 2001 Nov;27(5 Pt 1):563-71.
Affiliations
- PMID: 11694855
Clinical Trial
Predictors of response to glimepiride in patients with type 2 diabetes mellitus
G Charpentier et al. Diabetes Metab. 2001 Nov.
Abstract
Objective: The purpose of DIAMETRE (DIabète et Amarel en Monothérapie. Etude de Titration pour la définition des Répondeurs) was to identify factors predictive of response to glimepiride monotherapy in type 2 diabetic patients in the setting of a prospective multicentre open study.
Material and methods: Patients aged 35-70 years with poorly controlled diabetes [fasting plasma glucose (FPG) > or =1,40 g/l and < 3 g/l at baseline] were treated with glimepiride for 6 months, with dosage titrated from 1-6 mg daily, depending on the monthly FPG measurement. Responders were defined as patients with a) FPG < 7.78 mmol/l (1.40 g/l) and HbA(1c) < 7.5% at endpoint, or b) decrease in FPG > or = 20% and/or HbA1c > or = 10%. Stepwise logistic regression analysis was used to identify factors predictive of response.
Results: Of 849 patients evaluable for efficacy, 483 (56.9%) were responders. The response was independently influenced by prior treatment with OADs [OR: 0.399 (0.290-0.549), p=0.0001] and diabetes duration [OR: 0.912 (0.877-0.948), p=0.0001]. Ninety patients (9.2%) experienced 124 episodes of symptomatic hypoglycaemia. Multivariate analysis revealed that a high level of HbA(1c) decreased the risk of symptomatic hypoglycaemia [OR: 0.734 (0.628; 0.858), p=0.0001] whereas a family history of type 2 diabetes doubled this risk [OR: 1.956 (1.246; 3.072), p=0.003].
Conclusion: This large-scale study, conducted under conditions approximating to current medical practice, confirms that glimepiride has a favourable risk-benefit ratio in type 2 diabetes mellitus. Diabetes duration and previous treatment with OADs reduced the likelihood of being a responder to treatment.
Similar articles
- Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Luis Bautista J, Bugos C, Dirnberger G, Atherton T. Luis Bautista J, et al. Clin Ther. 2003 Jan;25(1):194-209. doi: 10.1016/s0149-2918(03)90025-7. Clin Ther. 2003. PMID: 12637120 Clinical Trial. - Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S. Ferrannini E, et al. Diabetes Obes Metab. 2009 Feb;11(2):157-66. doi: 10.1111/j.1463-1326.2008.00994.x. Diabetes Obes Metab. 2009. PMID: 19125777 Clinical Trial. - Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group. Blonde L, et al. Diabetes Obes Metab. 2009 Jun;11(6):623-31. doi: 10.1111/j.1463-1326.2009.01060.x. Diabetes Obes Metab. 2009. PMID: 19515182 Clinical Trial. - Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR. Nauck M, et al. Diabetes Obes Metab. 2013 Mar;15(3):204-12. doi: 10.1111/dom.12012. Epub 2012 Oct 11. Diabetes Obes Metab. 2013. PMID: 22985213 Review. - Clinical profile of glimepiride.
Draeger E. Draeger E. Diabetes Res Clin Pract. 1995 Aug;28 Suppl:S139-46. doi: 10.1016/0168-8227(95)01072-l. Diabetes Res Clin Pract. 1995. PMID: 8529506 Review.
Cited by
- Prospective Study Reveals Host Microbial Determinants of Clinical Response to Fecal Microbiota Transplant Therapy in Type 2 Diabetes Patients.
Ding D, Yong H, You N, Lu W, Yang X, Ye X, Wang Y, Cai T, Zheng X, Chen H, Cui B, Zhang F, Liu X, Mao JH, Lu Y, Chang H. Ding D, et al. Front Cell Infect Microbiol. 2022 Mar 25;12:820367. doi: 10.3389/fcimb.2022.820367. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35402293 Free PMC article. Clinical Trial. - Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum.
Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JC, Leiter LA, Leroith D, Defronzo R, Cefalu WT. Raz I, et al. Diabetes Care. 2013 Jun;36(6):1779-88. doi: 10.2337/dc13-0512. Diabetes Care. 2013. PMID: 23704680 Free PMC article. - Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience.
Anichini R, Cosimi S, Di Carlo A, Orsini P, De Bellis A, Seghieri G, Franconi F, Baccetti F. Anichini R, et al. Diabetes Metab Syndr Obes. 2013 Apr 8;6:123-9. doi: 10.2147/DMSO.S42729. Print 2013. Diabetes Metab Syndr Obes. 2013. PMID: 23630427 Free PMC article. - Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.
Schweizer A, Dejager S, Foley JE. Schweizer A, et al. Diabetes Ther. 2012 Nov;3(1):8. doi: 10.1007/s13300-012-0008-5. Epub 2012 Jun 27. Diabetes Ther. 2012. PMID: 22736406 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous